A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone

Inclusion Criteria: * Male and female patients eligible if 10 years of age, up to 17 years and 30 weeks of age at the time of screening * Previously diagnosed as having type 2 diabetes * HbA1c ≥7.0% and ≤10.5% * Body weight ≥ 30 kg * Stable dose of metformin (≥ 1000mg - ≤ 2000mg) for a minimum of 2 months * Women must have a negative serum or urine pregnancy test * Women must not be breastfeeding Exclusion Criteria: * Current use of anti-diabetic medications or use within the specified timeframe prior to screening (Exception: Metformin) * Fasting plasma glucose (FPG) \> 255 mg/dL * Diabetic ketoacidosis (DKA) within 6 months of study entry * Abnormal renal function * Active liver disease * Anemia * An abnormal Thyroid Stimulating Hormone (TSH) * Creatinine kinase (CK) ≥ 3X ULN